This whitepaper is aimed at those involved in managing drug safety operations in life sciences
organizations across the world and explores the most significant challenges facing life sciences
organizations in complying with E2B(R3). It explores the approaches that an organization might
want to consider to ensure compliance with the new requirement while streamlining their systems
and processes for improved operational effectiveness.